Cargando…
Novel diagnostic and prognostic classifiers for prostate cancer identified by genome-wide microRNA profiling
PURPOSE: This study investigates the diagnostic and prognostic biomarker potential of miRNAs in prostate cancer (PC). RESULTS: We identified several new deregulated miRNAs between non-malignant (NM) and PC tissue samples and between more/less aggressive PC subgroups. We also developed and validated...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058715/ https://www.ncbi.nlm.nih.gov/pubmed/27120795 http://dx.doi.org/10.18632/oncotarget.8953 |
Sumario: | PURPOSE: This study investigates the diagnostic and prognostic biomarker potential of miRNAs in prostate cancer (PC). RESULTS: We identified several new deregulated miRNAs between non-malignant (NM) and PC tissue samples and between more/less aggressive PC subgroups. We also developed and validated a novel 13-miRNA diagnostic classifier with high sensitivity and specificity for PC. Finally, we trained a new 3-miRNA prognostic classifier (miR-185-5p+miR-221-3p+miR-326) that predicted time to biochemical recurrence (BCR) independently of routine clinicopathological variables in a training radical prostatectomy (RP) cohort (n = 126) as well as in two independent validation cohorts (n = 110 and n = 99). EXPERIMENTAL DESIGN: After RT-qPCR-based profiling of 752 miRNAs in 13 NM and 134 PC tissue samples (cohort 1), we selected 93 top candidate diagnostic/prognostic miRNAs for validation in two independent patient sets (cohort 2: 19 NM and 138 PC; cohort 3: 28 NM and 113 PC samples). Diagnostic potential was assessed by ROC curve analysis and prognostic potential by Kaplan-Meier, uni- and multivariate Cox regression analyses. BCR after RP was used as endpoint. CONCLUSIONS: This is the first report of a miRNA signature with significant independent prognostic value demonstrated in three PC patient cohorts. |
---|